Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus

OBJECTIVES: The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. Oral cannabinoid-containing medications (OCs) ameliorate chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome....

Full description

Saved in:

Bibliographic Details
Main Authors:	Cecilia T Costiniuk, Edward Mills, Curtis L Cooper
Format:	Article
Language:	English
Published:	Wiley 2008-01-01
Series:	Canadian Journal of Gastroenterology
Online Access:	http://dx.doi.org/10.1155/2008/725702
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
by: David N Moskovitz, et al.
Published: (2003-01-01)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01)

Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)

Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians
by: Curtis L Cooper, et al.
Published: (2008-01-01)

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy
by: Curtis Cooper, et al.
Published: (2014-01-01)

A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
by: Nisha Mistry, et al.
Published: (2009-01-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Pegylated-Interferon Alpha 2b and Ribavirin for Recurrent Hepatitis C after Liver Transplantation: From a Canadian Experience to Recommendations for Therapy
by: Mohamed Babatin, et al.
Published: (2005-01-01)

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
by: Naota Taura, et al.
Published: (2012-01-01)

Effect of Ribavirin on Hepatitis A Virus Replication In Vitro
by: Rabindra K Chaudhary, et al.
Published: (1992-01-01)

The Cannabinoids: An Overview. Therapeutic Implications in Vomiting and Nausea after Cancer Chemotherapy, in Appetite Promotion, in Multiple Sclerosis and in Neuroprotection
by: R Mechoulam, et al.
Published: (2001-01-01)

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin
by: Morris Sherman, et al.
Published: (2006-01-01)

Fasciitis Complicating Subcutaneous Injection of Interferon Beta
by: Curtis L Cooper, et al.
Published: (2000-01-01)

Factors influencing bone loss in anorexia nervosa: assessment and therapeutic options
by: Isabelle Legroux, et al.
Published: (2019-11-01)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
by: Hirokazu Suii, et al.
Published: (2017-01-01)

Parasitic Disease Screening among HIV Patients from Endemic Countries in a Toronto Clinic
by: Cecilia T Costiniuk, et al.
Published: (2012-01-01)

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon-Resistant Chronic Hepatitis C
by: Frank H Anderson, et al.
Published: (1997-01-01)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
by: Zehui Yan, et al.
Published: (2012-01-01)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01)

Cannabinoid Hyperemesis
by: Stephen Sullivan
Published: (2010-01-01)

Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: A Systematic Review and Meta-Analysis
by: Awad Al-Omari, et al.
Published: (2013-01-01)

A Case of Acute Hepatitis E Infection in a Patient with Non-Hodgkin Lymphoma Treated Successfully with Ribavirin
by: Hasan N. Y. Haboubi, et al.
Published: (2017-01-01)

Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey
by: M. Assem, et al.
Published: (2011-01-01)

Acute Hepatitis Induced by Alpha-Interferon in a Patient with Chronic Hepatitis C
by: Ivan Kraus, et al.
Published: (2001-01-01)

Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)
by: Robert P Myers, et al.
Published: (2011-01-01)

Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection
by: Yong Li, et al.
Published: (2016-01-01)

Warning Signs of Anorexia
by: Jacqueline Endaya, et al.
Published: (2012-09-01)

Warning Signs of Anorexia
by: Jacqueline Endaya, et al.
Published: (2012-09-01)

Blogs pró-anorexia
by: Gina Emanuela Pinheiro, et al.
Published: (2010-06-01)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
by: Anna Maruyama, et al.
Published: (2016-01-01)

Pilot Study of Ofloxacin and Interferon-Alpha Combination Therapy for Chronic Hepatitis C without Sustained Response to Initial Interferon Therapy
by: Masafumi Komatsu, et al.
Published: (1997-01-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy
by: Janina Bruening, et al.
Published: (2017-01-01)

Current issues of anorexia statistics
by: L. A. Davletshina, et al.
Published: (2021-11-01)

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success
by: Curtis L Cooper
Published: (2010-01-01)

Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen
by: Andrew Trigg, et al.
Published: (2019-02-01)